A recent study published in Genes & Diseases by researchers from University of Arkansas for Medical Sciences, Cantata Bio, Seattle Children's Research Institute and Fred Hutchinson Cancer Center uses an integrated multi-omics approach to uncover how the C/G fusion extensively rewires DNA methylation and enhancer activity, producing a leukemia-specific epigenetic landscape.

Genome-wide methylation profiling across C/G+ patient samples and C/G+ cell lines revealed a distinct global hypermethylation signature, affecting more than 90,000 CpG sites and involving over 20,000 genes. Remarkably, many up-regulated C/G-restricted genes showed promoter hypermethylation yet retained open chromatin states enriched with H3K27ac—highlighting a non-canonical mechanism where hypermethylation supports, rather than represses, transcriptional activation. These genes include key adhesion molecules, TGFβ/Wnt signaling components, and immunotherapeutic targets such as HPSE2, CMTM5, and GP1BA.
By integrating chromatin-state modeling with promoter capture Hi-C, the study demonstrates that C/G+ leukemia cells undergo extensive de novo promoter–enhancer looping, often independent of CTCF binding. These loops frequently originate at hypermethylated enhancer regions, suggesting that enhancer methylation helps stabilize oncogenic chromatin interactions. This structural rewiring aligns with major transcriptional programs that support leukemic proliferation, adhesion, and lineage plasticity.

A major highlight of the study is the identification of DNMT3B as a critical downstream effector of the C/G fusion. CUT&RUN mapping showed direct binding of C/G at the DNMT3B promoter, accompanied by elevated DNMT3B expression in C/G+ samples. Functional knockout of DNMT3B led to extensive hypomethylation—especially at enhancer-bound regions—and down-regulation of C/G-restricted oncogenes. Importantly, DNMT3B loss significantly enhanced sensitivity to the BCL-2 inhibitor venetoclax, overcoming the apoptotic resistance characteristic of this leukemia subtype, and highlighting DNMT3B-dependent enhancer regulation as a therapeutic vulnerability.

In summary, this study shows that the CBFA2T3-GLIS2 fusion reshapes the epigenome through enhancer-associated DNA methylation and DNMT3B-driven chromatin remodeling, creating a transcriptional program that fuels leukemic growth. These findings suggest that targeting DNMT3B-mediated epigenetic circuits may offer a promising therapeutic strategy for this high-risk pediatric leukemia subtype.


Reference
Title of Original Paper : Transcriptional rewiring by enhancer methylation in CBFA2T3-GLIS2–driven pediatric acute megakaryoblastic leukemia

Journal
Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

DOI : https://doi.org/10.1016/j.gendis.2025.101843

Funding Information:

• The US Department of Defense RCRP Program (No. HT9425-24-1-0932)
• The National Institute of General Medical Sciences (USA) (No. 2P20GM121293)
• The Marion B. Lyon New Scientist Development Award of Arkansas Children's Research Institute (USA) (No. LYON5069)
• The University of Arkansas for Medical Sciences and Arkansas Bioscience Institute (USA) (No. ABIRC4426)

# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus Cite Score: 8.4
Impact Factor: 9.4
# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Disease may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx ).

Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R

Contact Us: editor@genesndiseases.cn
X (formerly Twitter): @GenesNDiseases (https://x.com/GenesNDiseases)

# # # # # #